Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Shares Outstanding (Weighted Average) (2018 - 2025)

Historic Shares Outstanding (Weighted Average) for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $189.2 million.

  • Revolution Medicines' Shares Outstanding (Weighted Average) rose 1341.83% to $189.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.2 million, marking a year-over-year increase of 1341.83%. This contributed to the annual value of $167.7 million for FY2024, which is 4824.38% up from last year.
  • According to the latest figures from Q3 2025, Revolution Medicines' Shares Outstanding (Weighted Average) is $189.2 million, which was up 1341.83% from $188.6 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Shares Outstanding (Weighted Average) peaked at $189.2 million during Q3 2025, and registered a low of $72.8 million during Q4 2021.
  • Over the past 5 years, Revolution Medicines' median Shares Outstanding (Weighted Average) value was $108.1 million (recorded in 2023), while the average stood at $121.6 million.
  • Per our database at Business Quant, Revolution Medicines' Shares Outstanding (Weighted Average) surged by 120.01% in 2022 and then surged by 7370.64% in 2024.
  • Quarter analysis of 5 years shows Revolution Medicines' Shares Outstanding (Weighted Average) stood at $72.8 million in 2021, then increased by 10.74% to $80.6 million in 2022, then surged by 40.34% to $113.1 million in 2023, then surged by 48.24% to $167.7 million in 2024, then grew by 12.81% to $189.2 million in 2025.
  • Its last three reported values are $189.2 million in Q3 2025, $188.6 million for Q2 2025, and $188.1 million during Q1 2025.